Amazon-Berkshire-JPMorgan healthcare joint venture will be called Haven

The healthcare joint venture between Amazon, Berkshire Hathaway and JPMorgan Chase finally has a name: Haven.

The Boston-based entity, which was created by the companies at the start of 2018, intends to address the healthcare needs of the 1.1 million employees of the three businesses.

“We want to change the way people experience health care so that it is simpler, better, and lower cost,” Haven CEO Atul Gawande, MD, MPH, said in a statement Wednesday. “We’ll start small, learn from the experience of patients and continue to expand to meet their needs.”

The JV has been on a hiring spree over the last year, adding top names from the healthcare industry and bringing in technology execs. As the new company scales up, it is planning to continue recruiting and hiring, according to the press release.

Along with announcing the name, the joint venture launched a new website describing its vision for “better care.”

Specifically, the brand is focused on leveraging data and technology to drive better incentives, a better patient experience and a better system, the website states.

“The advances in modern medicine have been remarkable, but even with insurance, many Americans do not have the basics—because medical treatment and prescription drug costs are high, the system is hard to navigate, and patients don’t consistently get the right care for their needs,” the website reads.

Gawande, who has led the JV since June 2018, has met with employees of Amazon, Berkshire Hathaway and JPMorgan Chase to understand their healthcare experiences.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup